Aiom
Anno I | Numero 6 | Ottobre 2016
Comitato scientifico editoriale: Paolo A. Ascierto, Vanna Chiarion-Sileni
Editore: Intermedia – Direttore Responsabile: Mauro Boldrini
 
 
Notizie dalla ricerca
 
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
Antibodies inhibiting the programmed death receptor 1 (PD-1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD-1 blockade in patients with uveal melanoma has not been well characterized. Fifty-eight patients with stage IV uveal melanoma received PD-1 or PD-1 ligand (PD-L1) antibodies between 2009 and 2015 at 9 academic centers. Patients who were evaluable for response were eligible for the analysis. Imaging was …
Continua a leggere
 
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
Ipilimumab (Ipi) improves the survival of advanced melanoma patients with an incremental long-term benefit in 10-15% of patients. A tumor signature that correlates with this survival benefit could help optimizing individualized treatment strategies. Freshly frozen melanoma metastases were collected from patients treated with either Ipi alone (n: 7) or Ipi combined with a dendritic cell vaccine (TriMixDC-MEL) (n: 11). Samples were profiled by immunohistochemistry (IHC), whole …
Continua a leggere
 
The efficacy of anti-PD-1 agents in acral and mucosal melanoma
Therapeutic antibodies against programmed cell death receptor 1 (PD-1) are considered front-line therapy in metastatic melanoma. The efficacy of PD-1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described. A multi-institutional, retrospective cohort analysis identified adults with advanced acral and mucosal melanoma who received treatment with nivolumab or pembrolizumab as standard clinical practice through …
Continua a leggere
 
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis
Growing evidence suggests that concurrent loco-regional and systemic treatment modalities may lead to synergistic anti-tumor effects in advanced melanoma. In this retrospective multicenter study, we evaluate the use of electrochemotherapy (ECT) combined with ipilimumab or PD-1 inhibition. We investigated patients with unresectable or metastatic melanoma who received the combination of ECT and immune checkpoint blockade for distant or cutaneous metastases within 4 weeks. Clinical and …
Continua a leggere
 
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab. To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma. Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration of follow-up was 21 months. The study was performed in academic …
Continua a leggere
 
Appuntamenti AIOM
 
XVIII CONGRESSO NAZIONALE AIOM
Roma, 28 – 30 ottobre 2016
Link all'evento
 
MICRO-AMBIENTE TUMORALE. Antiangiogenici e immunoterapia: miti e realtà
Milano, 11 ottobre 2016
 
XIV NIBIT Meeting
CANCER BIO – Immunotherapy in Siena
Siena, 13 – 15 ottobre 2016
 
DIALOGHI SULL'IMMUNOTERAPIA DEI TUMORI DELL'AIOM CAMPANIA
Benevento, 18 ottobre 2016
Napoli, 20 ottobre 2016
 
4th International Conference TRANSLATIONAL RESEARCH IN ONCOLOGY
Meldola (FC), 8 novembre 2016
Forlì, 9 – 11 novembre 2016
 
NUOVE FRONTIERE DIAGNOSTICO-TERAPEUTICHE NELLE NEOPLASIE POLMONARI, RENALI E NEL MELANOMA
Varese, 12 novembre 2016
 
XXII CONGRESSO NAZIONALE IMI – Intergruppo Melanoma Italiano
Multidisciplinarità e integrazione intorno al paziente
Ragusa, 13 – 15 novembre 2016
 
First International Congress
CLINICAL NEEDS AND TRANSLATIONAL RESEARCH IN ONCOLOGY
Reggio Emilia, 28 – 29 novembre 2016
 
MELANOMA BRIDGE 2016
Napoli, 30 novembre – 3 dicembre 2016
 
IMMUNOTHERAPY BRIDGE 2016
Napoli, 30 novembre 2016
 
Questi e altri appuntamenti si possono consultare sul sito AIOM
www.aiom.it
 

 
Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Per contattare la redazione e commentare le notizie clicca qui: redazione
Per consultare i numeri arretrati della newsletter clicca qui: archivio
Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI

Questo progetto è stato realizzato con il contributo di